As presented on May 14, 2026
Member Content
Prostate cancer treatment is shifting toward ultra-hypofractionation. But which is superior: the procedural precision of HDR Monotherapy or the non-invasive efficiency of SBRT?
Join the ABS Resident Prostate Journal Club for an evidence-based breakdown of the latest 10-year prospective data. We will compare long-term biochemical control rates, analyze acute vs. late toxicities, and discuss the "vanishing art" of brachytherapy in the modern era of hypofractionated radiation.